二甲双胍对多囊卵巢综合征患者疗效及其对患者脂肪组织miR-25水平的影响

doi:10.12092/j.issn.1009-2501.2019.05.012

摘要/Abstract

摘要：

目的:分析二甲双胍对多囊卵巢综合征（PCOS）患者疗效及其对患者脂肪组织miR-25水平的影响。方法:选取2018年3月至2019年1月本院内分泌科及妇科门诊就诊PCOS患者76例，简单随机化法分为两组，各38例，对照组给予炔雌醇环丙孕酮片治疗，观察组在此基础上给予二甲双胍治疗，比较两组治疗6个疗程后总有效率、性激素结合蛋白（SHBG）、黄体生成素（LH）、睾酮（T）、卵泡刺激素（FSH）、雌二醇（E2）、空腹胰岛素（FINS）、胰岛素抵抗指数（HOMA-IR）、腰臀比（WHR）、体质量指数（BMI）、脂肪组织miR-25 mRNA水平。结果:治疗6个疗程后总有效率，观察组（94.74%）较对照组（76.32%）高（P＜0.05）；治疗6个疗程后，观察组SHBG较对照组升高更加显著，LH、T、FINS、HOMA-IR、WHR、BMI较对照组下降更加显著（P＜0.05）；两组治疗6个疗程后FSH、E2比较无显著差异（P＞0.05）；治疗6个疗程后，观察组miR-25 mRNA较对照组下降更加显著（P＜0.05）。结论:二甲双胍治疗PCOS可改善患者性激素水平与中心型肥胖状态，纠正内分泌异常现象，增加胰岛素敏感性，疗效显著，其机制可能与抑制脂肪组织中miR-25表达有关，miR-25靶向抑制剂可能是治疗PCOS的新思路。

关键词: 脂肪组织, 二甲双胍, miR-25, 多囊卵巢综合征, 疗效

Abstract:

AIM: To analyze the effect of metformin on patients with polycystic ovary syndrome (PCOS) and its effect on adipose tissue miR-25 level. METHODS: From March 2018 to January 2019, 76 patients with PCOS were enrolled in the department of endocrinology and gynecology in our hospital. The simple randomization method was used to divide them into two groups, 38 cases in each group. The control group was given ethinyl estradiol progesterone tablets. The observation group was given metformin on the basis of this, and the total effective rate, sex hormone binding protein (SHBG), luteinizing hormone (LH), testosterone (T), follicle stimulating hormone (FSH), and female two were compared after treatment for 6 courses. Alcohol (E2), fasting insulin (FINS), insulin resistance index (HOMA-IR), waist-to-hip ratio (WHR), body mass index (BMI), adipose tissue miR-25 mRNA level were counted. RESULTS:After treatment for 6 courses, the total effective rate was 94.74% higher than that of the control group (76.32%) (P<0.05). After 6 courses of treatment, SHBG in the observation group increased more significantly than that in the control group, while LH, T, FINS, HOMA-IR, WHR and BMI decreased more significantly than that in the control group (P<0.05). There was no significant difference in FSH and E2 between the two groups after 6 courses of treatment (P>0.05); after 6 courses of treatment, the expression of microRNA-25 in the observation group decreased more significantly than that in the control group (P<0.05).CONCLUSION:Metformin treatment of PCOS can improve the level of sex hormones and central obesity, correct endocrine abnormalities and increase insulin sensitivity. The mechanism may be related to the inhibition of miR-25 expression in adipose tissue. miR-25 targeting inhibitor provides new idea for treating PCOS.

Key words: adipose tissue, metformin, miR-25, polycystic ovary syndrome, efficacy

中图分类号:

郭良堂，林超，孙云，戴盛锋，张炳才，陈舒. 二甲双胍对多囊卵巢综合征患者疗效及其对患者脂肪组织miR-25水平的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 554-560.

GUO Liangtang, LIN Chao, SUN Yun, DAI Shengfeng, ZHANG Bingcai, CHEN Shu. Effects of metformin on patients with polycystic ovary syndrome and its effect on adipose tissue miR-25 level[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 554-560.

参考文献

［1］金武敏,林佳,王佩玉,等.非降调促排卵方案在多囊卵巢综合征患者行体外授精-胚胎移植治疗中的疗效比较［J］.中国临床药理学与治疗学,2016,21(10):1178-1184.
［2］Cadagan D,Khan R,Amer S.Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome［J］.Reprod Biol,2016,16(1):53-60.
［3］Paul C,Laganà AS,Maniglio P,et al.Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome:state-of-the-art and future perspectives［J］.Gynecol Endocrinol,2016,32(6):431-438.
［4］陈雅,叶碧绿,郑九嘉,等.血清及卵泡液抗苗勒管激素在多囊卵巢综合征患者体外受精促排卵治疗中的价值［J］.中国临床药理学与治疗学,2015,20(12):1405-1411.
［5］吕立群,李薇.多囊卵巢综合征合并胰岛素抵抗患者脂肪组织瘦素信号转导分子-JAK2和STAT3蛋白的表达及磷酸化研究［J］.中国妇幼保健,2016,31(19):3922-3925.
［6］Yuan X,Hu T,Zhao H,et al.Brown adipose tissue transplantation ameliorates polycystic ovary syndrome［J］.Proc Natl Acad Sci U S A,2016,113(10):2708-13.
［7］郭良堂,戴凌虹,陈红,等.多囊卵巢综合征患者脂肪组织miR-25和微小染色体维持蛋白7的表达水平及临床意义［J］.中国妇幼保健,2018,33(24):5943-5946.
［8］乐杰.妇产科学［M］.第7版.北京:人民卫生出版社,2008:316.
［9］刘金铃.达英35治疗多囊卵巢综合征的疗效评价［J］.中国实用医药,2017,12(23):130-131.
［10］Cree-Green M,Rahat H,Newcomer BR,et al.Insulin resistance, hyperinsulinemia, and mitochondria dysfunction in nonobese girls with polycystic ovarian syndrome［J］.J Endocr Soc,2017,1(7):931-944.
［11］Song DK, Hong YS,Sung YA,et al.Insulin resistance according to β-cell function in women with polycystic ovary syndrome and normal glucose tolerance［J］.Plos One,2017,12(5):e0178120.
［12］Gültepe I,Basaranoglu M,Süleymano?lu Y,et al.Ovaries are more vulnerable than hepatocytes for insulin resistance and hyperinsulinemia［J］.Turk J Gastroenterol,2016,27(1):62-67.
［13］高金金,侯丽辉,李妍,等.体质量指数正常的多囊卵巢综合征伴胰岛素抵抗患者的临床特征及胰岛素抵抗影响因素分析［J］.实用妇产科杂志,2017,33(03):46-49.
［14］程玲慧,李泽莲,颜士杰,等.胰岛素抵抗对多囊卵巢综合征育龄妇女生育能力的影响［J］.中国临床保健杂志,2016,19(2):163-165.
［15］荣晅,宋东峰,侯春丽,等.胰岛素抵抗对多囊卵巢综合征患者内分泌及卵巢形态的影响［J］.广西医科大学学报,2017,34(8):1149-1152.
［16］徐岚,熊煜.炔雌醇环丙孕酮联合二甲双胍对多囊卵巢综合征患者排卵的影响［J］.中国药房,2016,27(24):3368-3370.
［17］熊苗,朱海润,罗艳群,等.炔雌醇环丙孕酮片对PCOS患者血清抗苗勒氏管激素的影响［J］.现代妇产科进展,2018,27(03):195-197.
［18］张郡,宿宓,许良智,等.炔雌醇环丙孕酮片与去氧孕烯炔雌醇片的长期应用对多囊卵巢综合征的疗效及代谢安全性［J］.南方医科大学学报,2018,38(08):917-922.
［19］张彩宇,陶爱群,莫有珍.二甲双胍与炔雌醇环丙孕酮片联用对多囊卵巢综合征患者相关激素分泌水平的影响［J］.中国现代医学杂志,2016,26(9):85-88.
［20］秦凤,李春亮,张惠莉.二甲双胍对2型糖尿病模型大鼠胰岛素抵抗的影响［J］.中国组织工程研究,2017,21(12):1909-1914.
［21］赵晓兰,冯琳.二甲双胍联合维格列汀对多囊卵巢综合征合并糖代谢异常的临床疗效研究［J］.中国临床药理学杂志,2016,32(6):517-519.
［22］岳欣,全会标.多囊卵巢综合征患者性激素水平与胰岛素抵抗的相关性研究［J］.安徽医药,2016,20(2):386-388.
［23］Stener-Victorin E,Maliqueo M,Soligo M,et al.Changes in HbA1cand circulating and adipose tissue androgen levels in overweight‐obese women with polycystic ovary syndrome in response to electroacupuncture［J］.Obes Sci Pract,2016,2(4):426-435.
［24］Alshammari G,Khan R,Brameld J,et al.Gene expression of inflammatory markers in adipose tissue between obese women with polycystic ovary and normal obese women［J］.Eur Rev Med Pharmacol Sci,2017,21(5):1099-1105.
［25］Delitala AP,Capobianco G,Delitala G,et al.Polycystic ovary syndrome, adipose tissue and metabolic syndrome［J］.Arch Gynecol Obstet,2017,296(3):405-419.
［26］Nakamitsu PZ,Compri CM,de Fraia Pinto L,et al.Thalidomide controls adipose tissue inflammation associated with high-fat diet-induced obesity in mice［J］.Endocr Metab Immune Disord Drug Target,2015,15(2):151-158.
［27］Slutsky N,Vatarescu M,Haim Y,et al.Decreased adiponectin links elevated adipose tissue autophagy with adipocyte endocrine dysfunction in obesity［J］.Int J Obes(Lond),2016,40(6):912-920.
［28］Magliano DC,Penna-de-carvalho A,Vazquez-carrera M,et al.Short-term administration of GW501516 improves inflammatory state in white adipose tissue and liver damage in high-fructose-fed mice through modulation of the renin-angiotensin system［J］.Endocrine,2015,50(2):355-367.
［29］支翠菊,黄瑛,祁炜罡,等.microRNA在肥胖大鼠脂肪组织中的差异表达［J］.中西医结合心脑血管病杂志,2017,15(1):40-43.
［30］Hossain MM,Cao M,Wang Q,et a1.Altered expression of miRNAs in a dihydrotestosterone-induced rat PCOS model［J］.J Ovarian Res,2013,6(1):36.
［31］Setyowati Karolina D,Sepramaniam S,Tan HZ,et al.miR-25 and miR-92a regulate insulin Ibiosynthesis in rats［J］.RNA Biol,2013,10(8):1365-1378.
［32］Wu HL,Heneidi S,Chuang TY,et al.The expression of the miR-25/93/106b family of micro-RNAs in the adipose tissue of women with polycystic ovary syndrome［J］.J Clin Endocrinol Metab,2014,99(12):E2754-2761.
［33］Sirotkin AV,Ovcharenko D,Grossmann R,et al.Identification of MicroRNAs controlling human ovarian cell steroidogenesis via a genome‐scale screen［J］.J Cell Physiol,2010,219(2):415-420.
［34］Zhang H,Zuo Z,Lu X,et al.MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer［J］.Oncol Rep,2011,27(2):594-598.
［35］Petrocca F,Vecchione A,Croce CM.Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling［J］.Cancer Res,2008,68(20):8191-8194.

[1]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[2]	肖悦, 李唐菲, 薛乾富. 聚乙二醇干扰素-α治疗原发性血小板增多症的疗效和安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1049-1055.
[3]	王洁, 李龙, 陈凤, 刘胜菲. 二甲双胍干预肺纤维化发病机制的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 235-240.
[4]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[5]	王歆, 刘维英, 武晨, 开锦军, 梁雪杰, 常瑛璇. 二甲双胍调节AMPK/SREBP-1通路及在临床中的应用进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1049-1054.
[6]	晏玉奎, 胡建琴, 张冰. 新型和传统抗癫痫药物治疗新诊断部分性癫痫的临床研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 793-799.
[7]	王珍, 全海燕, 洪陈亮, 袁李佳龙, 秦旭平. 游泳运动通过促进自噬改善糖尿病小鼠肾功能的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 632-638.
[8]	杜尘, 田禾, 曹阳, 王拥军, 张岩. 从内分泌激素探讨多囊卵巢综合征诱发骨代谢异常的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(3): 328-333.
[9]	郝伟, 左东泽, 张俊秀, 蒋莉莉, 熊莺, 杨解人. 二甲双胍对TGF-β1诱导的大鼠肺泡上皮II型细胞间质转分化的影响[J]. 中国临床药理学与治疗学, 2021, 26(7): 744-752.
[10]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[11]	李筱旻, 金浩, 周文智, 杨汉跃, 邹婷, 郭洁, 徐平声. 盐酸二甲双胍缓释片在健康人体的生物等效性研究[J]. 中国临床药理学与治疗学, 2021, 26(4): 408-413.
[12]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.
[13]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[14]	林荣芳, 郑玮玮, 刘亦伟, 林翠鸿, 王长连, 黄品芳. 克罗恩病患者英夫利西单抗相关基因多态性与血药浓度及疗效关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1000-1006.
[15]	李桂女, 任少琳, 沈瑞明, 季永能, 蔡彩荣, 苏若. 二甲双胍联合糖皮质激素治疗伴糖耐量异常的系统性红斑狼疮患者的临床研究[J]. 中国临床药理学与治疗学, 2020, 25(6): 670-676.